DexCom Director Albert F. Osterloh IV Receives 7,061 RSU Award

What Happened

• Albert F. Osterloh IV, a director of DexCom, Inc. (DXCM), was granted 7,061 restricted stock units (RSUs) on February 26, 2026. The reported acquisition price is $0.00 (a grant), so the Form 4 records $0 as the transaction value. The RSUs represent a contingent right to receive one share of DexCom common stock per unit.

Key Details

• Transaction date: 2026-02-26; Transaction type: Award/Grant (code A).
• Shares/units granted: 7,061 RSUs; reported acquisition price: $0.00.
• Vesting: These RSUs vest in three equal annual installments from the grant date (per footnote F1).
• Ownership after transaction: Not specified in the provided filing.
• Filing timeliness: Reported and filed on 2026-02-26 (no late filing indicated).
• Legal note: Footnote F1 states the grant is exempt from Section 16(b)-3 and the RSUs are contingent rights to receive shares.

Context

• RSU grants are not open‑market purchases or sales; they are compensation awards subject to future vesting and potential forfeiture until vested. The Form 4 shows a grant (neutral to slightly bullish depending on context), but because shares are restricted and vest over time, this does not indicate immediate share ownership or sale.